ATE408605T1 - Polymorph von ä6,7-bis(2-methoxyethoxy)chinazolin-4-ylü-(3e) - Google Patents

Polymorph von ä6,7-bis(2-methoxyethoxy)chinazolin-4-ylü-(3e)

Info

Publication number
ATE408605T1
ATE408605T1 AT04710031T AT04710031T ATE408605T1 AT E408605 T1 ATE408605 T1 AT E408605T1 AT 04710031 T AT04710031 T AT 04710031T AT 04710031 T AT04710031 T AT 04710031T AT E408605 T1 ATE408605 T1 AT E408605T1
Authority
AT
Austria
Prior art keywords
bis
quinazolin
ethynyl
ethoxy
methoxy
Prior art date
Application number
AT04710031T
Other languages
English (en)
Inventor
Andre Bubendorf
Michael Hennig
Pirmin Hidber
Goesta Rimmler
Franziska Rohrer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32842701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE408605(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE408605T1 publication Critical patent/ATE408605T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04710031T 2003-02-17 2004-02-11 Polymorph von ä6,7-bis(2-methoxyethoxy)chinazolin-4-ylü-(3e) ATE408605T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03003587 2003-02-17

Publications (1)

Publication Number Publication Date
ATE408605T1 true ATE408605T1 (de) 2008-10-15

Family

ID=32842701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04710031T ATE408605T1 (de) 2003-02-17 2004-02-11 Polymorph von ä6,7-bis(2-methoxyethoxy)chinazolin-4-ylü-(3e)

Country Status (24)

Country Link
US (1) US7148231B2 (de)
EP (1) EP1597239B2 (de)
JP (1) JP4456079B2 (de)
KR (1) KR100797430B1 (de)
CN (1) CN100506803C (de)
AT (1) ATE408605T1 (de)
AU (1) AU2004212067C1 (de)
BR (1) BRPI0407520A (de)
CA (1) CA2514977C (de)
CO (1) CO5601019A2 (de)
DE (1) DE602004016628D1 (de)
DK (1) DK1597239T4 (de)
ES (1) ES2314373T5 (de)
HR (1) HRP20050707B1 (de)
IL (1) IL169975A (de)
MX (1) MXPA05008598A (de)
NO (1) NO330781B1 (de)
NZ (1) NZ541500A (de)
PL (1) PL225428B1 (de)
PT (1) PT1597239E (de)
RU (1) RU2376294C2 (de)
SI (1) SI1597239T2 (de)
WO (1) WO2004072049A1 (de)
ZA (1) ZA200506339B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
EP2436381A1 (de) 2006-06-27 2012-04-04 Sandoz AG Kristallisierung von Halogenwasserstoffen von pharmazeutischen Verbindungen
EP2054393A1 (de) 2006-07-28 2009-05-06 Synthon B.V. Kristallines erlotinib
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
ES2573931T3 (es) 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
KR101441930B1 (ko) * 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
EP2218713A1 (de) 2007-08-17 2010-08-18 Hetero Drugs Limited Vom Polymorph der Form B weitgehend freies Erlotinibhydrochloridpolymorph der Form A
WO2009025875A1 (en) * 2007-08-23 2009-02-26 Plus Chemicals Sa Stable formulations of crystalline erlotinib hcl
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
EP2213281A1 (de) 2009-02-02 2010-08-04 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-(3-ethinylphenyl)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin-Hydrochlorid
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
CN101987834B (zh) * 2010-06-13 2012-07-18 信泰制药（苏州）有限公司 一种结晶形态的盐酸埃罗替尼及其制备方法
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
WO2012150606A2 (en) 2011-05-03 2012-11-08 Cadila Healthcare Limited A process for preparing stable polymophic form of erlotinib hydrochloride
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
WO2016082879A1 (en) * 2014-11-27 2016-06-02 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
RU2610337C1 (ru) * 2015-12-10 2017-02-09 Индивидуальный предприниматель Михайлов Олег Ростиславович Кристаллическая β-модификация N-(3-этинилфенил)-6,7-бис(2 метоксиэтокси)хиназолин-4-амин гидрохлорида, способ её получения и фармацевтическая композиция на её основе
JP2019059685A (ja) * 2017-09-26 2019-04-18 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
JP2020090456A (ja) * 2018-12-05 2020-06-11 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6434574A (en) * 1987-07-30 1989-02-06 Mazda Motor Full mold casting device
ATE446955T1 (de) * 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
US5747498A (en) † 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
NZ508154A (en) * 1998-04-29 2003-07-25 Osi Pharm Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування

Also Published As

Publication number Publication date
US20040162300A1 (en) 2004-08-19
ZA200506339B (en) 2006-05-31
AU2004212067B2 (en) 2009-03-19
CN1751032A (zh) 2006-03-22
EP1597239B1 (de) 2008-09-17
HRP20050707B1 (hr) 2013-10-25
PT1597239E (pt) 2008-10-10
ES2314373T5 (es) 2022-10-11
JP2006521288A (ja) 2006-09-21
WO2004072049A1 (en) 2004-08-26
IL169975A (en) 2011-06-30
JP4456079B2 (ja) 2010-04-28
MXPA05008598A (es) 2005-11-04
US7148231B2 (en) 2006-12-12
AU2004212067A1 (en) 2004-08-26
PL225428B1 (pl) 2017-04-28
CO5601019A2 (es) 2006-01-31
HRP20050707A2 (en) 2006-07-31
DK1597239T4 (da) 2022-09-26
AU2004212067C1 (en) 2009-09-24
DE602004016628D1 (de) 2008-10-30
KR100797430B1 (ko) 2008-01-23
NO330781B1 (no) 2011-07-18
CN100506803C (zh) 2009-07-01
NZ541500A (en) 2008-03-28
KR20050095898A (ko) 2005-10-04
EP1597239A1 (de) 2005-11-23
ES2314373T3 (es) 2009-03-16
RU2005128774A (ru) 2006-05-10
SI1597239T2 (sl) 2022-10-28
BRPI0407520A (pt) 2006-02-14
DK1597239T3 (da) 2008-12-08
CA2514977A1 (en) 2004-08-26
PL378561A1 (pl) 2006-05-02
SI1597239T1 (sl) 2009-02-28
NO20053953L (no) 2005-08-31
RU2376294C2 (ru) 2009-12-20
CA2514977C (en) 2010-06-22
EP1597239B2 (de) 2022-07-20

Similar Documents

Publication Publication Date Title
DE602004016628D1 (de) POLYMORPH VON ä6,7-BIS(2-METHOXYETHOXY)CHINAZOLIN-4-YLü-(3E)
AP1434A (en) Stable polymorph of N-(3-Ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof.
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
ATE554087T1 (de) Neue kinaseinhibitoren
UA84167C2 (ru) Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
YU84603A (sh) Novi inhibitori tirozin kinaze
DE602004011924D1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
CY1110511T1 (el) Διαδικασια για την παρασκευη της 4-(3'-χλωρο-4'-φθοροανιλινο)-7-μεθοξυ-6-(3-μορφολινοπροποξυ)κουιναζολινης
YU66100A (sh) N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat
IS7822A (is) Samsetningar í augu til meðhöndlunar á augnháþrýstingi
BRPI0615272A2 (pt) inibidores de p38 map kinase e métodos para uso dos mesmos
DE602005027728D1 (de) Benzodiazepin-Derivate als ROCK-Kinasen Hemmer
BR0214611A (pt) Antagonistas vii de receptor ccr-3
WO2005097755A3 (de) Imidazolderivate als hemmer von tyrosinkinase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1597239

Country of ref document: EP